Modern Medical Laboratory Journal

Diabetic nephropathy is the most common cause of end-stage renal disease, accounting for 29% in Europe in 2018. As the prevalence of type 2 diabetes increases, the number of people with diabetes and end-stage renal disease requiring renal replacement therapy is also rising. End-stage renal disease and dialysis itself increase the risk of hypoglycemia and hyperglycemia, which are associated with adverse outcomes
Scientists from Cambridge University successfully tested an artificial pancreas on humans. The new technology could help people living with type 2 diabetes and who require kidney dialysis. A recent trial showed that the device can help patients safely manage their blood sugar levels. The new version of the artificial pancreas can function automatically. Unlike the artificial pancreas being used for type 1 diabetes, this version is a fully closed-loop system. In this study, they hypothesized that fully closed-loop insulin delivery may improve glycemic control compared to standard insulin therapy without increasing the risk of hypoglycemia in people with type 2 diabetes and end-stage renal disease undergoing maintenance dialysis in the outpatient setting.
Read more